Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Other Non-Current Assets (2023 - 2026)

Contineum Therapeutics' Other Non-Current Assets history spans 4 years, with the latest figure at $312000.0 for Q1 2026.

  • Quarterly Other Non-Current Assets rose 7700.0% to $312000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $312000.0 through Mar 2026, up 7700.0% year-over-year, with the annual reading at $256000.0 for FY2025, 8433.33% up from the prior year.
  • Other Non-Current Assets came in at $312000.0 for Q1 2026, up from $256000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $2.6 million in Q1 2024 to a low of $3000.0 in Q2 2024.
  • The 4-year median for Other Non-Current Assets is $221000.0 (2025), against an average of $493900.0.
  • The largest YoY upside for Other Non-Current Assets was 8766.67% in 2025 against a maximum downside of 99.85% in 2025.
  • Contineum Therapeutics' Other Non-Current Assets stood at $1.3 million in 2023, then crashed by 99.77% to $3000.0 in 2024, then soared by 8433.33% to $256000.0 in 2025, then rose by 21.88% to $312000.0 in 2026.
  • Per Business Quant, the three most recent readings for CTNM's Other Non-Current Assets are $312000.0 (Q1 2026), $256000.0 (Q4 2025), and $266000.0 (Q3 2025).